Alan Korman, Ph.D.
Dr. Korman is Senior Vice President of Human Immunology at Vir Biotechnology. Previously, he was Vice President for Immuno-Oncology Discovery at Bristol-Myers Squibb (BMS), where he led the development of biologics for tumor immunotherapy. Prior to BMS, he held various positions at Medarex. His tenure at BMS and Medarex led to the development of two approved breakthrough drugs for oncology, ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) and their combination, pioneering the approach of immune checkpoint blockade. Dr. Korman received his Ph.D. in Cellular and Developmental Biology from Harvard University and was a Whitehead Fellow at the Whitehead Institute at the Massachusetts Institute of Technology. He was also a staff scientist at the Institut Pasteur prior to moving to the biotechnology sector.
Gal Markel, M.D., Ph.D.
Prof. Markel is a Clinician and basic researcher, he is the Chief Scientist of the Ella Lemelbaum Institute for Immuno-Oncology, Sheba medical center and Associate Professor of Immunology (Tel Aviv University). Prof. Markel is an expert in Immuno-Oncology with broad experience in integrative platforms, including genetics, cell biology, animal models and immunology. He is the author of 88 scientific peer-reviewed articles and the inventor of 12 US patent and applicant of 11 other patent applications in various fields. Prof. Markel was the CSO and scientific founder of cCAM Biotherapeutics.
Jeff Weber, M.D., Ph.D.
Dr. Weber is a clinical consultant and SAB member, Deputy Director of the Perlmutter Cancer Center and Codirector of its Melanoma Program at NYU Langone Medical Center. Medical oncologist and translational clinical trialist with an interest in melanoma immunotherapy and its intersection with targeted therapy.
Pavel Pisa, M.D., Ph.D.
Dr. Pisa is a physician-scientist and former Head of Translational Medicine at Roche/Genentech, with broad experience in drug early and late clinical development from over 50 programs. Dr. Pisa has in-depth knowledge of the experimental and clinical challenges with real-life experience of successful translation of scientific findings into medicines and innovative treatment modalities. Dr. Pisa has behind him a distinguished academic clinical and scientific career at world-leading medical institutions with authorship of 115 highly-cited publications and patents within tumor immunology.
Giovanni Abbadessa M.D., Ph.D.
Giovanni Abbadessa is an MD, PhD, who specialized in Oncology in Italy, and in Genetical Oncology between the US and Italy. He is Vice President, Head of Oncology Early Development at Sanofi, leading teams on a dozen different clinical project (oncology and hematology) and clinical strategy on as many lab projects. Prior to joining Sanofi in 2017, he has worked in several biotech companies in Boston, leading preclinical and clinical research teams, working on Phases 1-3 clinical trials, medical affairs, strategy, business development, investor relations, board and partnership management. Giovanni authored 40+ peer-reviewed articles, 20+ oral conference presentations, 50+ poster presentations.